Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Aztreonam Lysine for Pseudomonas Infection Eradication Study

ClinicalTrials.gov ID: NCT01375049

Public ClinicalTrials.gov record NCT01375049. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients With Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Culture Positive for Pseudomonas Aeruginosa (PA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multi-center study in pediatric patients age 3 months to less than 18 years with cystic fibrosis (CF) and newly detected Pseudomonas aeruginosa (PA) pulmonary colonization/infection. All eligible participants will be treated with a 28-day course of Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily. After completion of study drug, subjects will be followed up through Day 196 for safety and recurrence of PA. The primary objective is to evaluate the proportion of participants with PA-negative cultures at all time points during a 6-month monitoring period (through Day 196) after cessation of AZLI treatment. Microbiological cultures will be obtained at Baseline, Day 28 (end of AZLI treatment), Day 56 (1 month after completing AZLI treatment), Day 112 (3 months after completing AZLI treatment), and Day 196 (6 months after completing AZLI treatment).

Study identification

NCT ID
NCT01375049
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gilead Sciences
Industry
Enrollment
105 participants

Conditions and interventions

Eligibility (public fields only)

Age range
3 Months to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2011
Primary completion
Apr 30, 2013
Completion
Apr 30, 2013
Last update posted
Jul 16, 2014

2011 – 2013

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
23
Facility City State ZIP Site status
Phoenix Children's Hospital Phoenix Arizona 85016
Nemours Children's Clinic- Jacksonville Jacksonville Florida 32207
Nemours Childrens Clinic Orlando Orlando Florida 32801
Children's Memorial Hospital Chicago Illinois 60614
Riley Hospital for Children Indianapolis Indiana 46202
Children's Hospital Boston Boston Massachusetts 02115
University of Michigan Ann Arbor Michigan 48109
Children's Mercy Hospital and Clinics Kansas City Missouri 64108
Saint Louis University St Louis Missouri 63104
Cohen Children's Medical Center of NY Great Neck New York 11021
SUNY Upstate Medical University Syracuse New York 13210
UNC Chapel Hill Chapel Hill North Carolina 27599
Akron Children's Hospital Akron Ohio 44308
Cincinnati Children's Hospital Cincinnati Ohio 45229
Nationwide Children's Hospital Columbus Ohio 43205
Toledo Children's Hospital CF Research Center Toledo Ohio 43606
PennState Milton S. Hershey Medical Center Hershey Pennsylvania 17033
St. Christopher's Hospital for Children Philadelphia Pennsylvania 19134
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15224
Vanderbilt Children's Hospital Nashville Tennessee 37232
Baylor College of Medicine Houston Texas 77030
University of Utah Salt Lake City Utah 84108
Children's Hospital of Wisconsin Milwaukee Wisconsin 53201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01375049, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 16, 2014 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01375049 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →